<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JCN</journal-id>
<journal-id journal-id-type="hwp">spjcn</journal-id>
<journal-id journal-id-type="nlm-ta">J Child Neurol</journal-id>
<journal-title>Journal of Child Neurology</journal-title>
<issn pub-type="ppub">0883-0738</issn>
<issn pub-type="epub">1708-8283</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0883073812448437</article-id>
<article-id pub-id-type="publisher-id">10.1177_0883073812448437</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Resource Utilization in Children With Tuberous Sclerosis Complex and Associated Seizures</article-title>
<subtitle>A Retrospective Chart Review Study</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Lennert</surname>
<given-names>Barb</given-names>
</name>
<degrees>RN, BSN, MAOM</degrees>
<xref ref-type="aff" rid="aff1-0883073812448437">1</xref>
<xref ref-type="corresp" rid="corresp1-0883073812448437"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Farrelly</surname>
<given-names>Eileen</given-names>
</name>
<degrees>MPH</degrees>
<xref ref-type="aff" rid="aff1-0883073812448437">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sacco</surname>
<given-names>Patricia</given-names>
</name>
<degrees>MPH, RPh</degrees>
<xref ref-type="aff" rid="aff2-0883073812448437">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pira</surname>
<given-names>Geraldine</given-names>
</name>
<degrees>RN</degrees>
<xref ref-type="aff" rid="aff3-0883073812448437">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Frost</surname>
<given-names>Michael</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-0883073812448437">3</xref>
</contrib>
</contrib-group>
<aff id="aff1-0883073812448437">
<label>1</label>Xcenda, LLC, Palm Harbor, FL, USA</aff>
<aff id="aff2-0883073812448437">
<label>2</label>Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA</aff>
<aff id="aff3-0883073812448437">
<label>3</label>Minnesota Epilepsy Group, PA, St. Paul, MN, USA</aff>
<author-notes>
<corresp id="corresp1-0883073812448437">Barb Lennert, RN, BSN, MAOM, Xcenda, LLC, 4114 Woodlands Parkway, Suite 500, Palm Harbor, FL 34685. Email: <email>barb.lennert@xcenda.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>28</volume>
<issue>4</issue>
<fpage>461</fpage>
<lpage>469</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>2</month>
<year>2012</year>
</date>
<date date-type="accepted">
<day>21</day>
<month>4</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Seizures are a hallmark manifestation of tuberous sclerosis complex, yet data characterizing resource utilization are lacking. This retrospective chart review was performed to assess the economic burden of tuberous sclerosis complex with neurologic manifestations. Demographic and resource utilization data were collected for 95 patients for up to 5 years after tuberous sclerosis complex diagnosis. Mean age at diagnosis was 3.1 years, with complex partial and infantile spasms as the most common seizure types. In the first 5 years post-diagnosis, 83.2% required hospitalization, 30.5% underwent surgery, and the majority of patients (90.5%) underwent ≥3 testing procedures. In 79 patients with a full 5 years of data, hospitalizations, intensive care unit stays, diagnostic testing, and rehabilitation services decreased over the 5-year period. Resource utilization is cost-intensive in children with tuberous sclerosis complex and associated seizures during the first few years following diagnosis. Improving seizure control and reducing health care costs in this population remain unmet needs.</p>
</abstract>
<kwd-group>
<kwd>tuberous sclerosis complex (TSC)</kwd>
<kwd>seizures</kwd>
<kwd>resource utilization</kwd>
<kwd>epilepsy</kwd>
<kwd>economic burden</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>Tuberous sclerosis complex is a multisystem genetic disorder that causes pervasive benign tumors in the brain and other vital organs, including the kidneys, lungs, heart, eyes, and skin.<sup>
<xref ref-type="bibr" rid="bibr1-0883073812448437">1</xref>
</sup> It is the result of defects or mutations in the <italic>TSC1</italic> and/or <italic>TSC2 </italic>tumor suppressor genes, with most cases representing a new spontaneous genetic mutation, rather than an inherited mutation.<sup>
<xref ref-type="bibr" rid="bibr2-0883073812448437">2</xref>
</sup> Tuberous sclerosis complex is estimated to affect as many as 25 000 to 40 000 individuals in the United States and about 1 to 2 million worldwide, with an estimated prevalence of 1 in 6000 newborns.<sup>
<xref ref-type="bibr" rid="bibr2-0883073812448437">2</xref>
</sup>
</p>
<p>As tuberous sclerosis complex commonly affects the central nervous system, seizures, developmental delays, and behavioral problems are associated neurologic manifestations often evident in the first year of life, but may be more subtle, taking years to develop.<sup>
<xref ref-type="bibr" rid="bibr3-0883073812448437">3</xref>
</sup> Seizures rank as the most frequent neurologic manifestation and a major source of general morbidity and mortality in the tuberous sclerosis complex population.<sup>
<xref ref-type="bibr" rid="bibr4-0883073812448437">4</xref>
<xref ref-type="bibr" rid="bibr5-0883073812448437"/>
<xref ref-type="bibr" rid="bibr6-0883073812448437"/>
<xref ref-type="bibr" rid="bibr7-0883073812448437"/>
<xref ref-type="bibr" rid="bibr8-0883073812448437"/>–<xref ref-type="bibr" rid="bibr9-0883073812448437">9</xref>
</sup> It is well appreciated that the majority of patients with tuberous sclerosis complex experience seizures, with estimates ranging from 60% to more than 90% of patients.<sup>
<xref ref-type="bibr" rid="bibr4-0883073812448437">4</xref>,<xref ref-type="bibr" rid="bibr6-0883073812448437">6</xref>,<xref ref-type="bibr" rid="bibr10-0883073812448437">10</xref>
<xref ref-type="bibr" rid="bibr11-0883073812448437"/>–<xref ref-type="bibr" rid="bibr12-0883073812448437">12</xref>
</sup> In the pediatric tuberous sclerosis complex population, multiple seizure types are common.<sup>
<xref ref-type="bibr" rid="bibr4-0883073812448437">4</xref>,<xref ref-type="bibr" rid="bibr13-0883073812448437">13</xref>
</sup> Infantile spasms are the most common form of seizure presentation in patients with tuberous sclerosis complex. In addition, tuberous sclerosis complex may present as Lennox-Gastaut syndrome, a severe form of epilepsy.<sup>
<xref ref-type="bibr" rid="bibr13-0883073812448437">13</xref>,<xref ref-type="bibr" rid="bibr14-0883073812448437">14</xref>
</sup> Seizure control is difficult in this population, with 85% of children continuing to have seizures at the age of 5 years.<sup>
<xref ref-type="bibr" rid="bibr10-0883073812448437">10</xref>
</sup> These seizures have the potential to intensify long-term cognitive and behavioral disorders in patients with tuberous sclerosis complex. There are various approaches to seizure control, including drug therapy and surgery for those patients with epileptogenic tubers.<sup>
<xref ref-type="bibr" rid="bibr13-0883073812448437">13</xref>,<xref ref-type="bibr" rid="bibr15-0883073812448437">15</xref>
<xref ref-type="bibr" rid="bibr16-0883073812448437"/>
<xref ref-type="bibr" rid="bibr17-0883073812448437"/>
<xref ref-type="bibr" rid="bibr18-0883073812448437"/>–<xref ref-type="bibr" rid="bibr19-0883073812448437">19</xref>
</sup> Despite the antiepileptic drug therapy options available, the lack of seizure control remains an area of unmet need in this population.</p>
<p>Numerous diagnostic and routine screening evaluations are recommended as part of the clinical management of tuberous sclerosis complex.<sup>
<xref ref-type="bibr" rid="bibr10-0883073812448437">10</xref>,<xref ref-type="bibr" rid="bibr20-0883073812448437">20</xref>
<xref ref-type="bibr" rid="bibr21-0883073812448437"/>–<xref ref-type="bibr" rid="bibr22-0883073812448437">22</xref>
</sup> However, data characterizing resource utilization among patients with tuberous sclerosis complex and associated seizures are lacking. As such, the objective of this retrospective chart review study was to characterize resource utilization in patients with tuberous sclerosis complex–associated seizures. In addition, assessing disease progression (including clinical flow and treatment patterns) during the first 5 years post-diagnosis of tuberous sclerosis complex was an outcome of interest.</p>
<sec id="section1-0883073812448437" sec-type="methods">
<title>Methods</title>
<sec id="section2-0883073812448437">
<title>Data Collection</title>
<p>This study was a retrospective medical record review of patient data collected at, and reported by, Minnesota Epilepsy Group, PA, via a secure, password-protected, Web-based data collection tool. Minnesota Epilepsy Group is the largest and most comprehensive epilepsy program in the Midwest area of the United States. All data were entered into a secure, Web-based, Microsoft Access data collection tool developed by Xcenda, and hosted on Xcenda’s server. Charts of all patients were deidentified at the study site; only investigators involved in the study had access to study data. All data were reviewed by a principal investigator, a registered nurse with significant experience in neurology and chart review studies.</p>
<p>Data collection was conducted during the period of January 13 to April 11, 2011, using data available from 1973 to 2010. Of the 115 clinic patients with a tuberous sclerosis complex diagnosis and at least 6 months of available data, 95 patients with a tuberous sclerosis complex–related seizure diagnosis were included in the seizure cohort. To be included in this cohort, patients were required to be diagnosed with a tuberous sclerosis complex–related seizure disorder within the first 6 months after tuberous sclerosis complex diagnosis. Patients were excluded if they were diagnosed with a tuberous sclerosis complex–unrelated seizure disorder. The target sample size was 150 charts; however, only 115 charts were available at Minnesota Epilepsy Group that met the aforementioned criteria.</p>
<p>Variables of interest included demographics (eg, date of birth, gender, date of tuberous sclerosis complex diagnosis), seizure type and frequency during the first 6 months after diagnosis, clinical information (eg, comorbid/associated conditions, medications, ketogenic diet), resource utilization (eg, magnetic resonance imaging [MRI] and other scans/tests—including computed tomographic [CT] scans, electrocardiograms, electroencephalograms [EEGs], and ultrasounds—neuropsychological testing, hospitalizations, surgeries, rehabilitation services), and outcomes (eg, living arrangements/disposition).</p>
<p>Data were collected for 3 time periods: (1) Pre–Tuberous Sclerosis Complex Data Collection Period (ie, date of birth or start of medical records at Minnesota Epilepsy Group through tuberous sclerosis complex diagnosis) captured all preexisting, comorbid, and associated conditions; (2) Post–Index Date Period I (ie, 6 months after tuberous sclerosis complex diagnosis) established the seizure cohort; and (3) Post–Index Date Period II (ie, 5 years after tuberous sclerosis complex diagnosis) captured resource utilization data (<xref ref-type="fig" rid="fig1-0883073812448437">Figure 1</xref>). For Post–Index Date Periods I and II, if less than 5 years of data were available, as much data as possible were collected, with a minimum requirement of 6 months of available data.</p>
<fig id="fig1-0883073812448437" position="float">
<label>Figure 1.</label>
<caption>
<p>Study design: data collection periods. DOB indicates date of birth; MEG, Minnesota Epilepsy Group.</p>
</caption>
<graphic alternate-form-of="fig1-0883073812448437" xlink:href="10.1177_0883073812448437-fig1.tif"/>
</fig>
<p>All data access, use, and reporting were conducted in a manner compliant with the Health Insurance Portability and Accountability Act, thus ensuring that the confidentiality and privacy of patients were maintained. In keeping with Good Clinical Practice, the study protocol, protocol amendments, and all other study forms were reviewed and approved by Minnesota Epilepsy Group’s independent institutional review board prior to study implementation.</p>
</sec>
<sec id="section3-0883073812448437">
<title>Statistical Analysis</title>
<p>Descriptive statistics (eg, means, frequencies) were generated on the basis of the characteristics of the particular variable of interest and followed generally accepted convention. Resource utilization rates (ie, the proportions of patients utilizing the service) in the various cohorts were compared using McNemar’s tests for correlated proportions. The level of significance (alpha) was set a priori to 0.05. All statistical analyses were conducted with SAS software, version 9.1 (SAS Corp, Cary, NC).</p>
</sec>
</sec>
<sec id="section4-0883073812448437">
<title>Results</title>
<p>Ninety-five patients with a confirmed tuberous sclerosis complex diagnosis and at least 6 months of follow-up data met the criteria for inclusion in the seizure cohort for whom patient characteristics, medication treatment patterns, and resource utilization are reported herein.</p>
<sec id="section5-0883073812448437">
<title>Overall Population</title>
<sec id="section6-0883073812448437">
<title>Demographic and clinical characteristics</title>
<p>Baseline demographic and clinical characteristics of the seizure cohort are displayed in <xref ref-type="table" rid="table1-0883073812448437">Table 1</xref>. The study population had a mean age at tuberous sclerosis complex diagnosis of 3.1 years and was evenly divided with respect to gender (50.5% female). Approximately, one-third of patients had genetic testing. Of those with genetic testing results, a spontaneous mutation of <italic>TSC2</italic> was identified in 39.4% of patients; 36.4% were reported as having indeterminate tuberous sclerosis complex testing.</p>
<table-wrap id="table1-0883073812448437" position="float">
<label>Table 1.</label>
<caption>
<p>Baseline Demographic and Clinical Characteristics.</p>
</caption>
<graphic alternate-form-of="table1-0883073812448437" xlink:href="10.1177_0883073812448437-table1.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>Seizure cohort (N = 95)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (SD) at TSC diagnosis, years</td>
<td>3.1 (7.8)</td>
</tr>
<tr>
<td>Age at diagnosis in years, n (%)</td>
<td>
</td>
</tr>
<tr>
<td> 0-1</td>
<td>60 (63.2)</td>
</tr>
<tr>
<td> 1.5-5</td>
<td>22 (23.2)</td>
</tr>
<tr>
<td> 5.5-10</td>
<td>7 (7.4)</td>
</tr>
<tr>
<td> 10.5-18</td>
<td>2 (2.1)</td>
</tr>
<tr>
<td> 18.5-40</td>
<td>2 (2.1)</td>
</tr>
<tr>
<td> 40.5-50</td>
<td>2 (2.1)</td>
</tr>
<tr>
<td>Gender, n (%)</td>
<td>
</td>
</tr>
<tr>
<td> Female</td>
<td>48 (50.5)</td>
</tr>
<tr>
<td> Male</td>
<td>47 (49.5)</td>
</tr>
<tr>
<td>At least 1 sibling with neurologic disorder, n (%)</td>
<td>14 (14.7)</td>
</tr>
<tr>
<td> 1 sibling</td>
<td>9 (9.5)</td>
</tr>
<tr>
<td> 2 siblings</td>
<td>4 (4.2)</td>
</tr>
<tr>
<td>TSC genetic testing, n (%)</td>
<td>
</td>
</tr>
<tr>
<td> Completed</td>
<td>33 (34.7)</td>
</tr>
<tr>
<td> Not completed</td>
<td>16 (16.8)</td>
</tr>
<tr>
<td> Unknown</td>
<td>46 (48.4)</td>
</tr>
<tr>
<td>Type of <italic>TSC</italic> mutation (n = 33), n (%<sup>a</sup>)</td>
<td>
</td>
</tr>
<tr>
<td> Indeterminate</td>
<td>12 (36.4)</td>
</tr>
<tr>
<td> <italic>TSC1</italic> spontaneous</td>
<td>6 (18.2)</td>
</tr>
<tr>
<td> <italic>TSC2</italic> genetic</td>
<td>2 (6.1)</td>
</tr>
<tr>
<td> <italic>TSC2</italic> spontaneous</td>
<td>13 (39.4)</td>
</tr>
<tr>
<td>Additional genetic mutation detected (n = 33), n (%<sup>a</sup>)</td>
<td>3 (9.1)</td>
</tr>
<tr>
<td>History of ketogenic diet use, n (%)</td>
<td>5 (5.3)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0883073812448437">
<p>Abbreviations: SD, standard deviation; TSC, tuberous sclerosis complex.</p>
</fn>
<fn id="table-fn2-0883073812448437">
<p>
<sup>a</sup>Based on the subset of 33 patients completing TSC genetic testing.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>Clinical manifestations or associated conditions of tuberous sclerosis complex were common and consistent with those expected in this population, including tumors (94.7%), skin abnormalities (90.5%), neurologic disorders (83.2%), and developmental disorders (62.1%) (<xref ref-type="table" rid="table2-0883073812448437">Table 2</xref>). Global developmental delay was reported in 35 (36.84%) patients; these 35 patients represent 59.3% of patients with a development disorder. The following conditions were also reported, with the corresponding percentages of patients in this cohort of tuberous sclerosis complex patients with seizures: language/speech disorder or delay, 14.7%; mental retardation, 13.7%; and autism spectrum disorder, 12.6%.</p>
<table-wrap id="table2-0883073812448437" position="float">
<label>Table 2.</label>
<caption>
<p>Comorbid Conditions.</p>
</caption>
<graphic alternate-form-of="table2-0883073812448437" xlink:href="10.1177_0883073812448437-table2.tif"/>
<table>
<thead>
<tr>
<th>Condition</th>
<th>No. of patients (N = 95)</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neurologic disorders</td>
<td>79</td>
<td>83.16</td>
</tr>
<tr>
<td> Lennox-Gastaut syndrome</td>
<td>3</td>
<td>3.16</td>
</tr>
<tr>
<td> West syndrome/infantile spasms</td>
<td>33</td>
<td>34.74</td>
</tr>
<tr>
<td> Febrile seizure</td>
<td>2</td>
<td>2.11</td>
</tr>
<tr>
<td> Status epilepticus</td>
<td>11</td>
<td>11.58</td>
</tr>
<tr>
<td> Epilepsy</td>
<td>73</td>
<td>76.84</td>
</tr>
<tr>
<td>Developmental disorders</td>
<td>59</td>
<td>62.11</td>
</tr>
<tr>
<td> Global development delay</td>
<td>35</td>
<td>36.84</td>
</tr>
<tr>
<td> Learning disabilities</td>
<td>2</td>
<td>2.11</td>
</tr>
<tr>
<td> Mental retardation</td>
<td>13</td>
<td>13.68</td>
</tr>
<tr>
<td>  Mild</td>
<td>5</td>
<td>38.46</td>
</tr>
<tr>
<td>  Moderate</td>
<td>3</td>
<td>23.08</td>
</tr>
<tr>
<td>  Severe</td>
<td>5</td>
<td>38.46</td>
</tr>
<tr>
<td> Language or speech disorder or delay</td>
<td>14</td>
<td>14.74</td>
</tr>
<tr>
<td> Autism spectrum disorder</td>
<td>12</td>
<td>12.63</td>
</tr>
<tr>
<td>Eye</td>
<td>22</td>
<td>23.16</td>
</tr>
<tr>
<td> Phakomas</td>
<td>1</td>
<td>1.05</td>
</tr>
<tr>
<td> Retinal hamartomas or astrocytomas</td>
<td>17</td>
<td>17.89</td>
</tr>
<tr>
<td> Retinal achromic patch</td>
<td>1</td>
<td>1.05</td>
</tr>
<tr>
<td> Other eye disorder</td>
<td>6</td>
<td>6.32</td>
</tr>
<tr>
<td>Renal disorders</td>
<td>30</td>
<td>31.58</td>
</tr>
<tr>
<td> Renal angiomyolipomas</td>
<td>24</td>
<td>25.26</td>
</tr>
<tr>
<td>  Symptomatic</td>
<td>2</td>
<td>8.33</td>
</tr>
<tr>
<td>  Asymptomatic</td>
<td>22</td>
<td>91.67</td>
</tr>
<tr>
<td> Renal cysts</td>
<td>12</td>
<td>12.63</td>
</tr>
<tr>
<td>  Symptomatic</td>
<td>2</td>
<td>16.67</td>
</tr>
<tr>
<td>  Asymptomatic</td>
<td>10</td>
<td>83.33</td>
</tr>
<tr>
<td> Polycystic kidney disease</td>
<td>2</td>
<td>2.11</td>
</tr>
<tr>
<td>Cardiac disorders </td>
<td>44</td>
<td>46.32</td>
</tr>
<tr>
<td> Cardiac rhabdomyomas</td>
<td>43</td>
<td>45.26</td>
</tr>
<tr>
<td>  Symptomatic</td>
<td>6</td>
<td>13.95</td>
</tr>
<tr>
<td>  Asymptomatic</td>
<td>37</td>
<td>86.05</td>
</tr>
<tr>
<td> Wolff-Parkinson-White syndrome</td>
<td>4</td>
<td>4.21</td>
</tr>
<tr>
<td> Hypertension</td>
<td>2</td>
<td>2.11</td>
</tr>
<tr>
<td> Other cardiac disorder</td>
<td>8</td>
<td>8.42</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>6</td>
<td>6.32</td>
</tr>
<tr>
<td> Feeding disorder</td>
<td>3</td>
<td>3.16</td>
</tr>
<tr>
<td> Gastroesophageal reflux disease</td>
<td>4</td>
<td>4.21</td>
</tr>
<tr>
<td>Oral cavity disorders</td>
<td>1</td>
<td>1.05</td>
</tr>
<tr>
<td> Dental enamel pitting</td>
<td>1</td>
<td>1.05</td>
</tr>
<tr>
<td>Tumors</td>
<td>90</td>
<td>94.74</td>
</tr>
<tr>
<td> Subependymal giant cell astrocytomas</td>
<td>12</td>
<td>12.63</td>
</tr>
<tr>
<td> Subependymal nodules</td>
<td>82</td>
<td>86.32</td>
</tr>
<tr>
<td> Cortical tubers</td>
<td>77</td>
<td>81.05</td>
</tr>
<tr>
<td> Nonrenal hamartoma</td>
<td>3</td>
<td>3.16</td>
</tr>
<tr>
<td>Neuropsychiatric disorders</td>
<td>17</td>
<td>17.89</td>
</tr>
<tr>
<td> Attention-deficit hyperactivity disorder</td>
<td>6</td>
<td>6.32</td>
</tr>
<tr>
<td> Disruptive behavior disorder</td>
<td>7</td>
<td>7.37</td>
</tr>
<tr>
<td> Anxiety disorder</td>
<td>2</td>
<td>2.11</td>
</tr>
<tr>
<td> Mood disorder</td>
<td>4</td>
<td>4.21</td>
</tr>
<tr>
<td> Other neuropsychiatric disorders</td>
<td>2</td>
<td>2.11</td>
</tr>
<tr>
<td>Skin abnormalities</td>
<td>86</td>
<td>90.53</td>
</tr>
<tr>
<td> Hypomelanotic macules</td>
<td>60</td>
<td>63.16</td>
</tr>
<tr>
<td> Ash leaf spots</td>
<td>22</td>
<td>23.16</td>
</tr>
<tr>
<td> Facial angiofibromas</td>
<td>40</td>
<td>42.11</td>
</tr>
<tr>
<td> Forehead plaque</td>
<td>4</td>
<td>4.21</td>
</tr>
<tr>
<td> Shagreen patches</td>
<td>13</td>
<td>13.68</td>
</tr>
<tr>
<td> Ungal or periungal fibromas</td>
<td>1</td>
<td>1.05</td>
</tr>
<tr>
<td> Café au lait spots</td>
<td>12</td>
<td>12.63</td>
</tr>
<tr>
<td> Adenoma sebaceum</td>
<td>1</td>
<td>1.05</td>
</tr>
<tr>
<td> Confetti skin lesions</td>
<td>3</td>
<td>3.16</td>
</tr>
<tr>
<td>Other medical disorders</td>
<td>28</td>
<td>29.47</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>In review of the seizure types recorded during the first 6 months after seizure diagnosis, the most common seizure type was complex partial (n = 44; 46.3%), followed by infantile spasms (n = 33; 34.7%), simple partial (n = 13; 13.7%), and partial/secondary generalized (n = 11; 11.6%), with all other types occurring at a frequency &lt;10%. Nearly half of the cohort was reported as having daily seizures (n = 54; 47.0%, mean of 3.59/d), with the remainder having weekly (n = 14; 12.2%, mean of 2.11/wk), monthly (n = 17; 14.8%, mean of 2.67/mo), too many to count (n = 19; 16.5%), or unknown (n = 8; 7.0%) frequencies.</p>
</sec>
<sec id="section7-0883073812448437">
<title>Medication treatment patterns</title>
<p>The majority of medications used on a routine basis were anticonvulsants (<xref ref-type="table" rid="table3-0883073812448437">Table 3</xref>), the most common being sodium valproate (54.7%), levetiracetam (46.3%), and topiramate (44.2%).</p>
<table-wrap id="table3-0883073812448437" position="float">
<label>Table 3.</label>
<caption>
<p>Most Commonly Used (≥20%) Routine Medications.</p>
</caption>
<graphic alternate-form-of="table3-0883073812448437" xlink:href="10.1177_0883073812448437-table3.tif"/>
<table>
<thead>
<tr>
<th>Medication (routine use)</th>
<th>No. of patients (N = 95)</th>
<th>%<sup>a</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carbamazepine</td>
<td>37</td>
<td>38.95</td>
</tr>
<tr>
<td>Clonazepam</td>
<td>21</td>
<td>22.11</td>
</tr>
<tr>
<td>Felbamate</td>
<td>26</td>
<td>27.37</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>19</td>
<td>20.00</td>
</tr>
<tr>
<td>Lamotrigine</td>
<td>36</td>
<td>37.89</td>
</tr>
<tr>
<td>Levetiracetam</td>
<td>44</td>
<td>46.32</td>
</tr>
<tr>
<td>Oxcarbazepine</td>
<td>36</td>
<td>37.89</td>
</tr>
<tr>
<td>Phenobarbital</td>
<td>34</td>
<td>35.79</td>
</tr>
<tr>
<td>Sodium valproate</td>
<td>52</td>
<td>54.74</td>
</tr>
<tr>
<td>Topiramate</td>
<td>42</td>
<td>44.21</td>
</tr>
<tr>
<td>Vigabatrin<sup>b</sup>
</td>
<td>27</td>
<td>28.42</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-0883073812448437">
<p>
<sup>a</sup>Medications with &lt;20% usage included acetazolamide, adrenocorticotropic hormone, clorazepate, corticosteroids, diazepam, ethotoin, ethosuximide, everolimus, lacosamide, methsuximide, phenytoin, pregabalin, primidone, rufinamide, tiagabine, and zonisamide.</p>
</fn>
<fn id="table-fn4-0883073812448437">
<p>
<sup>b</sup>Although there is solid clinical evidence and guideline recommendations supporting use of vigabatrin to interrupt seizures (and therefore reduce the cognitive and behavioral consequences of the seizures in tuberous sclerosis complex patients, particularly those with infantile spasms<sup>
<xref ref-type="bibr" rid="bibr23-0883073812448437">23</xref>
</sup>), vigabatrin was first approved for use in the United States in August 2009. Given that the data collected spanned 1973-2010, vigabatrin was available during only a small percentage of this time period, and therefore the likely reason that &lt;30% of those in this study reflect utilization of this drug that has become a mainstay in the treatment of seizures in tuberous sclerosis complex patients.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0883073812448437">
<title>Resource utilization</title>
<p>The proportions of patients requiring hospitalizations and intensive care unit stays, surgeries, testing procedures, and rehabilitative services are summarized in <xref ref-type="table" rid="table4-0883073812448437">Table 4</xref>, with key findings highlighted herein.</p>
<table-wrap id="table4-0883073812448437" position="float">
<label>Table 4.</label>
<caption>
<p>Resource Utilization Summary.</p>
</caption>
<graphic alternate-form-of="table4-0883073812448437" xlink:href="10.1177_0883073812448437-table4.tif"/>
<table>
<thead>
<tr>
<th>Outcomes/utilization measure</th>
<th>No. of patients (N = 95)</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospitalizations</td>
<td>79</td>
<td>83.16</td>
</tr>
<tr>
<td> Neurologic and/or TSC related</td>
<td>76</td>
<td>80.00</td>
</tr>
<tr>
<td> All neurologic related</td>
<td>53</td>
<td>55.79</td>
</tr>
<tr>
<td> All TSC related</td>
<td>51</td>
<td>53.68</td>
</tr>
<tr>
<td> Other—all<sup>a</sup>
</td>
<td>13</td>
<td>13.68</td>
</tr>
<tr>
<td> Other—only<sup>b</sup>
</td>
<td>3</td>
<td>3.16</td>
</tr>
<tr>
<td> Other (with either neurologic and/or TSC)<sup>c</sup>
</td>
<td>10</td>
<td>10.53</td>
</tr>
<tr>
<td>Intensive care unit stays</td>
<td>21</td>
<td>22.11</td>
</tr>
<tr>
<td>Surgeries</td>
<td>29</td>
<td>30.53</td>
</tr>
<tr>
<td> Resective</td>
<td>8</td>
<td>8.42</td>
</tr>
<tr>
<td> Vagus nerve stimulation</td>
<td>5</td>
<td>5.26</td>
</tr>
<tr>
<td> Indwelling electrodes with resection</td>
<td>6</td>
<td>6.32</td>
</tr>
<tr>
<td> Indwelling electrodes without resection</td>
<td>3</td>
<td>3.16</td>
</tr>
<tr>
<td> Corpus callosotomy, partial</td>
<td>4</td>
<td>4.21</td>
</tr>
<tr>
<td> Corpus callosotomy, complete</td>
<td>1</td>
<td>1.05</td>
</tr>
<tr>
<td> Laser treatment for facial angiofibromas</td>
<td>2</td>
<td>2.11</td>
</tr>
<tr>
<td> Other</td>
<td>15</td>
<td>15.79</td>
</tr>
<tr>
<td>Testing</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Electroencephalograms</td>
<td>89</td>
<td>93.68</td>
</tr>
<tr>
<td> Magnetoencephalography</td>
<td>7</td>
<td>7.37</td>
</tr>
<tr>
<td> Computed tomography</td>
<td>53</td>
<td>55.79</td>
</tr>
<tr>
<td>  Head</td>
<td>45</td>
<td>47.37</td>
</tr>
<tr>
<td>  Chest</td>
<td>7</td>
<td>7.37</td>
</tr>
<tr>
<td>  Abdomen</td>
<td>15</td>
<td>15.79</td>
</tr>
<tr>
<td> Magnetic resonance imaging</td>
<td>86</td>
<td>90.53</td>
</tr>
<tr>
<td>  Head</td>
<td>86</td>
<td>90.53</td>
</tr>
<tr>
<td>  Chest</td>
<td>1</td>
<td>1.05</td>
</tr>
<tr>
<td>  Abdomen</td>
<td>10</td>
<td>10.53</td>
</tr>
<tr>
<td> Single-photon emission computed tomography</td>
<td>6</td>
<td>6.32</td>
</tr>
<tr>
<td>  Head</td>
<td>5</td>
<td>5.26</td>
</tr>
<tr>
<td> Positron emission tomography</td>
<td>16</td>
<td>16.84</td>
</tr>
<tr>
<td>  Head</td>
<td>16</td>
<td>16.84</td>
</tr>
<tr>
<td> Pulmonary function testing</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td> Electrocardiograms</td>
<td>33</td>
<td>34.74</td>
</tr>
<tr>
<td> Echocardiograms</td>
<td>74</td>
<td>77.89</td>
</tr>
<tr>
<td> Renal ultrasounds</td>
<td>71</td>
<td>74.74</td>
</tr>
<tr>
<td> Neuropsychiatric testing</td>
<td>23</td>
<td>24.21</td>
</tr>
<tr>
<td>Rehabilitation services</td>
<td>41</td>
<td>43.16</td>
</tr>
<tr>
<td> Physical therapy</td>
<td>30</td>
<td>31.58</td>
</tr>
<tr>
<td> Occupational therapy</td>
<td>33</td>
<td>34.74</td>
</tr>
<tr>
<td> Speech-language pathology</td>
<td>33</td>
<td>34.74</td>
</tr>
<tr>
<td> Special education</td>
<td>14</td>
<td>14.74</td>
</tr>
<tr>
<td> Other</td>
<td>6</td>
<td>6.32</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0883073812448437">
<p>Abbreviation: TSC, tuberous sclerosis complex.</p>
</fn>
<fn id="table-fn6-0883073812448437">
<p>
<sup>a</sup>All patients with an "other" hospitalization included.</p>
</fn>
<fn id="table-fn7-0883073812448437">
<p>
<sup>b</sup>Only includes patients with an "other" hospitalization that did not have either neurologic or TSC-related hospitalization.</p>
</fn>
<fn id="table-fn8-0883073812448437">
<p>
<sup>c</sup>Only includes patients with an "other" hospitalization that also had either neurologic or TSC-related hospitalization.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section9-0883073812448437">
<title>Hospitalizations and intensive care unit stays during first 5 years after tuberous sclerosis complex diagnosis</title>
<p>Hospitalizations were common during the first 5 years after tuberous sclerosis complex diagnosis, and were recorded for 83.2% of patients. Overall, the mean number of hospitalizations was 0.50 per year/patient and the average length of stay was 6.22 days. For neurologic-related hospitalizations, the mean number was 0.28 per year/patient and the average stay was 6.03 days. Corresponding data for tuberous sclerosis complex–related hospitalizations were 0.18 per year/patient and the average stay was 6.80 days, and for other-related hospitalizations, the mean number was 0.04 per year/patient and the average length of stay was 4.88 days. Intensive care unit stays were required for 22.1% of patients, with a mean number of 0.06 per year/patient and an average length of stay of 3.26 days.</p>
</sec>
<sec id="section10-0883073812448437">
<title>Surgeries</title>
<p>Surgeries were performed in 30.5% of patients, with 8.4% having resective surgery (the most common individual surgery type), followed by indwelling electrodes without resection (6.3%), vagus nerve stimulation (5.3%), and partial corpus callosotomy (4.2%). There were 15 “other” surgeries, which included myringotomy (n = 3), pressure equalizer tube placement (n = 2), percutaneous endoscopic gastrostomy placement (n = 2), and tonsillectomy and/or adenoidectomy (n = 3). All other surgeries (eg, salpingo-oophorectomy, excisions of a fibroma, or ventricular rhabdomyoma) were performed in individual patients.</p>
</sec>
<sec id="section11-0883073812448437">
<title>Testing</title>
<p>MRI and CT scans were performed in 90.5% and 55.8% of patients, respectively; 50% of patients had 3 or more head MRIs. EEGs were performed in 93.7% of patients; 85.4% of whom had routine EEGs, 64.0% had long-term EEGs, and 51.7% had both types of EEGs. Magnetoencephalographic scans were performed in 7.4% of patients. Overall, the majority of patients (90.5%) underwent 3 or more testing procedures (<xref ref-type="fig" rid="fig2-0883073812448437">Figure 2</xref>).</p>
<fig id="fig2-0883073812448437" position="float">
<label>Figure 2.</label>
<caption>
<p>Number of testing procedures performed during the follow-up period (N = 95). Testing includes magnetic resonance imaging, computed tomography, electroencephalogram, magnetoencephalography, single-photon emission computed tomography, positron emission tomography, pulmonary function testing, electrocardiograms, echocardiograms, renal ultrasounds, and neuropsychological testing. </p>
</caption>
<graphic alternate-form-of="fig2-0883073812448437" xlink:href="10.1177_0883073812448437-fig2.tif"/>
</fig>
</sec>
<sec id="section12-0883073812448437">
<title>Rehabilitation services</title>
<p>Rehabilitation services were provided to 43.2% of patients; 34.7% of patients received speech-language pathology and occupational therapy services, whereas physical therapy and special education services were provided to 31.6% and 14.7% of patients, respectively.</p>
</sec>
<sec id="section13-0883073812448437">
<title>Disposition</title>
<p>At the end of the Post–Index Date Period II, 95.8% of patients were living at home; the remaining patients were at home with paid home care services (3.2%) or in foster care (1.1%).</p>
</sec>
</sec>
<sec id="section14-0883073812448437">
<title>Subanalyses</title>
<sec id="section15-0883073812448437">
<title>Five-year results</title>
<p>There were 79 patients who had a full 5 years of data. In this subset of patients, the mean numbers of hospitalizations, intensive care unit stays, diagnostic testing, and rehabilitation services decreased over the 5-year period, when comparing year 1 to year 5 (<xref ref-type="table" rid="table5-0883073812448437">Table 5</xref>). Conversely, the need for surgery was near the same frequency at years 1 and 5, with an increase at year 3.</p>
<table-wrap id="table5-0883073812448437" position="float">
<label>Table 5.</label>
<caption>
<p>Five-Year Results in Patients With 5 Full Years of Follow-Up (N = 79).</p>
</caption>
<graphic alternate-form-of="table5-0883073812448437" xlink:href="10.1177_0883073812448437-table5.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">
</th>
<th colspan="5">Mean number per year per patient</th>
</tr>
<tr>
<th>Year 1</th>
<th>Year 2</th>
<th>Year 3</th>
<th>Year 4</th>
<th>Year 5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospitalizations</td>
<td>0.95</td>
<td>0.43</td>
<td>0.38</td>
<td>0.28</td>
<td>0.24</td>
</tr>
<tr>
<td> Neurologic related</td>
<td>0.52</td>
<td>0.32</td>
<td>0.23</td>
<td>0.16</td>
<td>0.13</td>
</tr>
<tr>
<td> TSC related</td>
<td>0.37</td>
<td>0.09</td>
<td>0.11</td>
<td>0.09</td>
<td>0.10</td>
</tr>
<tr>
<td> Other related</td>
<td>0.06</td>
<td>0.03</td>
<td>0.04</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td>Intensive care unit stays</td>
<td>0.09</td>
<td>0.04</td>
<td>0.08</td>
<td>0.03</td>
<td>0.01</td>
</tr>
<tr>
<td>Surgeries</td>
<td>0.10</td>
<td>0.09</td>
<td>0.18</td>
<td>0.10</td>
<td>0.09</td>
</tr>
<tr>
<td>Testing<sup>a</sup>
</td>
<td>5.09</td>
<td>1.84</td>
<td>1.76</td>
<td>1.16</td>
<td>1.33</td>
</tr>
<tr>
<td>Rehabilitation services</td>
<td>0.37</td>
<td>0.34</td>
<td>0.24</td>
<td>0.13</td>
<td>0.14</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn9-0883073812448437">
<p>Abbreviation: TSC, tuberous sclerosis complex.</p>
</fn>
<fn id="table-fn10-0883073812448437">
<p>
<sup>a</sup>Testing includes magnetic resonance imaging, computed tomography, electroencephalogram, magnetoencephalography, single-photon emission computed tomography, positron emission tomography, pulmonary function testing, electrocardiograms, echocardiograms, renal ultrasounds, and neuropsychological testing.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section16-0883073812448437">
<title>Specific subgroups: associated conditions</title>
<p>All of the resource utilization data for the overall seizure cohort were analyzed by the following 3 subgroups: neurologic disorders, West syndrome/infantile spasms, and developmental disorders. This secondary analysis was conducted to further characterize resource utilization by these associated conditions (<xref ref-type="table" rid="table6-0883073812448437">Table 6</xref>). Those with a neurologic disorder or West syndrome/infantile spasms showed significantly more hospitalizations (<italic>P</italic> = 0.0049 and <italic>P</italic> = 0.0405, respectively). Those with a developmental disorder did not have significantly more hospitalizations, but they did have significantly more intensive care unit stays (<italic>P</italic> = 0.0024). In all 3 subgroups, patients with these associated conditions experienced significantly increased utilization of physical therapy, occupational therapy, and speech-language pathology, as well as certain testing procedures (<xref ref-type="table" rid="table6-0883073812448437">Table 6</xref>).</p>
<table-wrap id="table6-0883073812448437" position="float">
<label>Table 6.</label>
<caption>
<p>Specific Subgroup Analyses<sup>a</sup>: Associated Conditions.</p>
</caption>
<graphic alternate-form-of="table6-0883073812448437" xlink:href="10.1177_0883073812448437-table6.tif"/>
<table>
<thead>
<tr>
<th>
</th>
<th>No associated neurologic condition</th>
<th>Neurologic condition</th>
<th>
<italic>P</italic> value<sup>b</sup>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients</td>
<td>16</td>
<td>79</td>
<td>
</td>
</tr>
<tr>
<td> Age (mean)</td>
<td>7.9</td>
<td>2.1</td>
<td>0.08</td>
</tr>
<tr>
<td> Gender (% female)</td>
<td>50.0</td>
<td>50.6</td>
<td>0.96</td>
</tr>
<tr>
<td>Outcomes (%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Hospitalizations</td>
<td>56.3</td>
<td>88.6</td>
<td>0.0049</td>
</tr>
<tr>
<td>  Neurologic and/or TSC-related</td>
<td>56.3</td>
<td>84.8</td>
<td>0.0092</td>
</tr>
<tr>
<td>  All neurologic related</td>
<td>25.0</td>
<td>62.0</td>
<td>0.0065</td>
</tr>
<tr>
<td>Testing (%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> 1 testing procedure</td>
<td>0.0</td>
<td>1.3</td>
<td rowspan="4">0.0095</td>
</tr>
<tr>
<td> 2 testing procedures</td>
<td>31.3</td>
<td>3.8</td>
</tr>
<tr>
<td> 3-5 testing procedures</td>
<td>50.0</td>
<td>62.0</td>
</tr>
<tr>
<td> &gt;5 testing procedures</td>
<td>18.8</td>
<td>32.9</td>
</tr>
<tr>
<td> Echocardiograms</td>
<td>56.3</td>
<td>82.3</td>
<td>0.0421</td>
</tr>
<tr>
<td>Rehabilitation services (%)</td>
<td>12.5</td>
<td>49.4</td>
<td>0.0066</td>
</tr>
<tr>
<td> Physical therapy</td>
<td>0.0</td>
<td>38.0</td>
<td>0.0029</td>
</tr>
<tr>
<td> Occupational therapy</td>
<td>6.3</td>
<td>40.5</td>
<td>0.0087</td>
</tr>
<tr>
<td> Speech-language pathology</td>
<td>12.5</td>
<td>39.2</td>
<td>0.0405</td>
</tr>
<tr>
<th>
</th>
<th align="center">No associated West syndrome/infantile spasms</th>
<th>West syndrome/infantile spasms</th>
<th>
<italic>P </italic>value</th>
</tr>
<tr>
<td>No. of patients</td>
<td>62</td>
<td>33</td>
<td> </td>
</tr>
<tr>
<td> Age (mean)</td>
<td>4.5</td>
<td>0.4</td>
<td>0.0011</td>
</tr>
<tr>
<td> Gender (% female)</td>
<td>54.8</td>
<td>42.4</td>
<td>0.25</td>
</tr>
<tr>
<td>Outcomes (%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Hospitalizations</td>
<td>77.4</td>
<td>93.9</td>
<td>0.0405</td>
</tr>
<tr>
<td>  Other-only<sup>c</sup>
</td>
<td>0.0</td>
<td>9.1</td>
<td>.0394</td>
</tr>
<tr>
<td>Testing (%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Positron emission tomography</td>
<td>11.3</td>
<td>27.3</td>
<td>0.0475</td>
</tr>
<tr>
<td>  Head</td>
<td>11.3</td>
<td>27.3</td>
<td>0.0475</td>
</tr>
<tr>
<td>Rehabilitation services (%)</td>
<td>35.5</td>
<td>57.6</td>
<td>0.0385</td>
</tr>
<tr>
<td> Physical therapy</td>
<td>22.6</td>
<td>48.5</td>
<td>0.0097</td>
</tr>
<tr>
<td> Occupational therapy</td>
<td>25.8</td>
<td>51.5</td>
<td>0.0122</td>
</tr>
<tr>
<td> Speech language pathology</td>
<td>27.4</td>
<td>48.5</td>
<td>0.0401</td>
</tr>
<tr>
<td>
</td>
<td align="center">No associated developmental disorders</td>
<td align="center">Developmental disorders </td>
<td align="center">
<italic>P</italic>-value</td>
</tr>
<tr>
<td>No. of patients</td>
<td>36</td>
<td>59</td>
<td> </td>
</tr>
<tr>
<td> Age (mean)</td>
<td>5.9</td>
<td>1.4</td>
<td>0.0220</td>
</tr>
<tr>
<td> Gender (% female)</td>
<td>58.3</td>
<td>45.8</td>
<td>0.23</td>
</tr>
<tr>
<td>Outcomes (%)</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Hospitalizations</td>
<td>77.8</td>
<td>86.4</td>
<td>0.27</td>
</tr>
<tr>
<td>  All TSC-related</td>
<td>38.9</td>
<td>62.7</td>
<td>0.0239</td>
</tr>
<tr>
<td> Intensive care unit stays</td>
<td>5.6</td>
<td>32.2</td>
<td>0.0024</td>
</tr>
<tr>
<td>Testing</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> 1 testing procedure</td>
<td>0.0</td>
<td>1.7</td>
<td rowspan="4">0.0043</td>
</tr>
<tr>
<td> 2 testing procedures</td>
<td>16.7</td>
<td>3.4</td>
</tr>
<tr>
<td> 3-5 testing procedures</td>
<td>69.4</td>
<td>54.2</td>
</tr>
<tr>
<td> &gt;5 testing procedures</td>
<td>13.9</td>
<td>40.7</td>
</tr>
<tr>
<td> Computed tomography</td>
<td>41.7</td>
<td>64.4</td>
<td>0.0304</td>
</tr>
<tr>
<td>  Head</td>
<td>33.3</td>
<td>55.9</td>
<td>0.0323</td>
</tr>
<tr>
<td> Echocardiograms</td>
<td>52.8</td>
<td>93.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Rehabilitation services</td>
<td>5.6</td>
<td>66.1</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td> Physical therapy</td>
<td>5.6</td>
<td>47.5</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td> Occupational therapy</td>
<td>2.8</td>
<td>54.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td> Speech-language pathology</td>
<td>2.8</td>
<td>54.2</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td> Special education</td>
<td>2.8</td>
<td>22.0</td>
<td>0.0102</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn11-0883073812448437">
<p>Abbreviation: TSC, tuberous sclerosis complex.</p>
</fn>
<fn id="table-fn12-0883073812448437">
<p>
<sup>a</sup>For all subgroup analyses, only those with statistical significance were reported in <xref ref-type="table" rid="table6-0883073812448437">Table 6</xref>; however, all of the following were assessed for each subgroup: hospitalizations (neurologic, TSC related, and other), intensive care unit stay, testing (electroencephalogram; magnetoencephalography; scans of head, chest, and abdomen via computed tomography; magnetic resonance imaging; single-photon emission computed tomography; or positron emission tomography; pulmonary function testing; electrocardiogram; echocardiogram; renal ultrasound; neuropsychological evaluation), and rehabilitation services (physical therapy, occupational therapy, speech-language pathology, special education, other).</p>
</fn>
<fn id="table-fn13-0883073812448437">
<p>
<sup>b</sup>The level of significance (alpha) was set a priori to 0.05.</p>
</fn>
<fn id="table-fn14-0883073812448437">
<p>
<sup>c</sup>Only includes patients with an "other" hospitalization who did not have either neurologic or TSC-related hospitalization.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
</sec>
</sec>
<sec id="section17-0883073812448437">
<title>Discussion</title>
<p>This retrospective chart review of patients with tuberous sclerosis complex and associated seizures confirms that utilization of health care services in the initial years following tuberous sclerosis complex diagnosis is cost-intensive.</p>
<p>To our knowledge, this is the first study that provides evidence of resource utilization in patients with tuberous sclerosis complex and associated seizures. Few studies have sought to characterize the economic and humanistic burden of tuberous sclerosis complex–associated seizures in children or adults, as concluded by a recently published systematic review of tuberous sclerosis complex with neurologic manifestations.<sup>
<xref ref-type="bibr" rid="bibr24-0883073812448437">24</xref>
</sup> There are data suggesting a high frequency of multiple seizure types in some tuberous sclerosis complex patients, resulting in the use of multiple anticonvulsant medications.<sup>
<xref ref-type="bibr" rid="bibr25-0883073812448437">25</xref>
</sup> Cost data for epilepsy in general (not specific to tuberous sclerosis complex) support that seizures are a cost-intensive condition and, as expected, translate into even higher costs when poorly controlled.<sup>
<xref ref-type="bibr" rid="bibr26-0883073812448437">26</xref>
<xref ref-type="bibr" rid="bibr27-0883073812448437"/>
<xref ref-type="bibr" rid="bibr28-0883073812448437"/>–<xref ref-type="bibr" rid="bibr29-0883073812448437">29</xref>
</sup> Early-onset seizures, such as infantile spasms, have been temporally associated with autistic regression,<sup>
<xref ref-type="bibr" rid="bibr30-0883073812448437">30</xref>,<xref ref-type="bibr" rid="bibr31-0883073812448437">31</xref>
</sup> whereas developmental disorders have been associated with the underlying disease physiology of tuberous sclerosis complex (eg, cortical tubers in certain regions of the brain), and seizure history.<sup>
<xref ref-type="bibr" rid="bibr32-0883073812448437">32</xref>
<xref ref-type="bibr" rid="bibr33-0883073812448437"/>
<xref ref-type="bibr" rid="bibr34-0883073812448437"/>–<xref ref-type="bibr" rid="bibr35-0883073812448437">35</xref>
</sup> Overall, the relationships between seizures, neurologic development, and neuropsychological disorders in tuberous sclerosis complex are seemingly complex and multifaceted and have substantial potential to translate into long-term disability and resource utilization attributable to the neurologic component of tuberous sclerosis complex.<sup>
<xref ref-type="bibr" rid="bibr10-0883073812448437">10</xref>,<xref ref-type="bibr" rid="bibr16-0883073812448437">16</xref>,<xref ref-type="bibr" rid="bibr17-0883073812448437">17</xref>,<xref ref-type="bibr" rid="bibr36-0883073812448437">36</xref>
<xref ref-type="bibr" rid="bibr37-0883073812448437"/>–<xref ref-type="bibr" rid="bibr38-0883073812448437">38</xref>
</sup> Although this study was focused on the first 5 years after tuberous sclerosis complex diagnosis, additional studies to address long-term resource utilization in patients with tuberous sclerosis complex and associated seizures are warranted. This study was not designed to investigate resource utilization based specifically on disease severity, so patients with more mild disease may not have been sufficiently represented.</p>
<p>In our sample, nearly half of the patients in whom tuberous sclerosis complex genetic testing had been completed had a <italic>TSC2</italic> mutation, commonly associated with infantile spasms, intellectual disability, and autism spectrum disorder, and had overall greater disease severity relative to patients with <italic>TSC1</italic> or unidentifiable mutations.<sup>
<xref ref-type="bibr" rid="bibr32-0883073812448437">32</xref>
</sup> Because the resource utilization data captured in this retrospective review date back to 1973, these findings cannot be compared against current guideline-recommended routine diagnostic and surveillance screening or treatment in the tuberous sclerosis complex population. However, the resource utilization–intensive nature of such guidelines is noteworthy and reflects the lack of a single diagnostic feature of tuberous sclerosis complex. The type and frequency of testing in the tuberous sclerosis complex population are driven by the timing of evaluation and directly influenced by the presentation of clinical symptoms.<sup>
<xref ref-type="bibr" rid="bibr10-0883073812448437">10</xref>,<xref ref-type="bibr" rid="bibr22-0883073812448437">22</xref>
</sup> Given the need for a comprehensive assessment covering all of the various clinical manifestations of tuberous sclerosis complex, the diagnosis and management of these patients require a specialized, multidisciplinary approach that may be critical to prevent long-term developmental impairment among children with associated seizures. Multidisciplinary clinics are being established for tuberous sclerosis complex because it is a multisystem, multidimensional disease. The physicians involved with the Minnesota Epilepsy Group tuberous sclerosis complex clinic include experts on adult and pediatric neurology/epilepsy, pediatric and adult urology, dermatology, pediatric cardiology, pediatric neurosurgery, genetics, and ophthalmology. Support personnel include adult and pediatric nurses (who also function as case managers and clinic coordinators), genetic counselors, nurse practitioners, social workers, research coordinators, neuropsychologists, and psychologists. Ancillary hospital staff include a dietician, a physiatrist, and a psychiatrist as well as occupational, physical, and speech therapists. All team members have specific and necessary roles in managing this complex disorder.</p>
<p>The results of this chart-review study provide limited information regarding medication treatment patterns, other than to illustrate the predominance of antiepileptic agents use. It is apparent that no single therapy has emerged for the effective management of seizures in this population, resulting in an unmet medical need to improve seizure control and reduce health care costs in this complex population.</p>
<p>The authors acknowledge several additional limitations of this study and its findings, including those inherent to retrospective analyses compared to a prospective assessment of the outcome of interest. First, although great care was taken to ensure the data collected were accurate and complete, results may have been affected by data quality, which was dependent on the completeness, accuracy, and integrity of the secondary source and data-collection process. Data were collected from Minnesota Epilepsy Group medical records; therefore, resource utilization in other health care settings (hospitals, other clinics, etc) may have been variably recorded. Second, as the study population was exclusively composed of Minnesota Epilepsy Group–treated patients, the generalizability of these results are limited, particularly to health care systems outside the United States with different diagnosis and treatment patterns, as well as different access to health care services. Third, this analysis was not designed to provide insight into the relative contribution of seizure-related vs-unrelated care, although there is evidence that unrelated-care costs comprise a major proportion of health care resource utilization among patients with non–tuberous sclerosis complex–specific seizure disorders in the United States.<sup>
<xref ref-type="bibr" rid="bibr39-0883073812448437">39</xref>,<xref ref-type="bibr" rid="bibr40-0883073812448437">40</xref>
</sup> Furthermore, although our study results support that observed direct costs are high, it does not characterize the full economic or humanistic burden of tuberous sclerosis complex and associated seizures. For example, in this study, data on all types of direct costs and indirect costs (such as productivity loss of parents/caregivers and specialized educational needs of school-age children) were not collected. Some additional resource utilization areas not factored into the analysis include emergency department visits and seizure-related injuries. Overall, some, but not all, of the costs of ongoing, routine surveillance required for this population were included. Finally, as no long-term data were collected, the extent to which the resource utilization may have changed beyond the first 5 years post-diagnosis remains an important outstanding question for which there is a paucity of data.<sup>
<xref ref-type="bibr" rid="bibr41-0883073812448437">41</xref>
</sup>
</p>
<p>In conclusion, the results of this retrospective analysis confirm that resource utilization is cost-intensive, particularly during the first few years following tuberous sclerosis complex diagnosis. Results also suggest that direct costs represent a major component of expenditures in managing patients with tuberous sclerosis complex and associated seizures. Further study of direct and indirect costs will help to better describe the humanistic and economic burden of tuberous sclerosis complex on individuals, families, and society.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgments</title>
<p>The authors acknowledge the contributions of Lindsey Reese, RN, and Catherine Folland, RN, of the Minnesota Epilepsy Group in the conduct of this study. The authors would also like to acknowledge Lorie Mody for her assistance in writing this manuscript.</p>
</ack>
<fn-group>
<fn fn-type="other" id="fn1-0883073812448437">
<label>Author Contributions</label>
<p>All authors were responsible for the study conception and design, analysis and interpretation of the data, revising the article critically for important intellectual content, and final approval of the published version.</p>
</fn>
<fn fn-type="conflict" id="fn2-0883073812448437">
<label>Declaration of Conflicting Interests</label>
<p>The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Author Sacco is an employee of Novartis. Authors Lennert and Farrelly are employees of Xcenda, a consulting company that received funding from Novartis to complete this study. Authors Pira and Frost are employees of Minnesota Epilepsy Group, PA. Minnesota Epilepsy Group was the study site and was compensated for its time in providing feedback on the study protocol and collecting the data, and for providing feedback on the data analysis, summary, and manuscript. </p>
</fn>
<fn fn-type="financial-disclosure" id="fn3-0883073812448437">
<label>Funding</label>
<p>The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by Novartis Pharmaceuticals Corporation. <bold> </bold>
</p>
</fn>
<fn fn-type="other" id="fn4-0883073812448437">
<label>Ethical Approval</label>
<p>All data access, use, and reporting were conducted in a manner compliant with the Health Insurance Portability and Accountability Act, thus ensuring that the confidentiality and privacy of patients were maintained. In keeping with Good Clinical Practice, the study protocol, protocol amendments, and all other study forms were reviewed and approved by Minnesota Epilepsy Group’s independent institutional review board prior to study implementation.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0883073812448437">
<label>1</label>
<citation citation-type="web">
<collab collab-type="author">National Institute of Neurological Disorders and Stroke</collab>. <article-title>Tuberous sclerosis fact sheet</article-title>. <comment>Available at</comment>: <ext-link ext-link-type="uri" xlink:href="http://www.ninds.nih.gov/disorders/tuberous_sclerosis/detail_tuberous_sclerosis.htm">http://www.ninds.nih.gov/disorders/tuberous_sclerosis/detail_tuberous_sclerosis.htm</ext-link>. <comment>Accessed September 19, 2011</comment>.</citation>
</ref>
<ref id="bibr2-0883073812448437">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dabora</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Jozwiak</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
<etal/>
</person-group>. <article-title>Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs</article-title>. <source>Am J Hum Genet</source>. <year>2001</year>;<volume>68</volume>:<fpage>64</fpage>–<lpage>80</lpage>.</citation>
</ref>
<ref id="bibr3-0883073812448437">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>D'Argenzio</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Cerminara</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bombardieri</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Management of epilepsy in tuberous sclerosis complex</article-title>. <source>Expert Rev Neurother</source>. <year>2008</year>;<volume>8</volume>:<fpage>457</fpage>–<lpage>467</lpage>.</citation>
</ref>
<ref id="bibr4-0883073812448437">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu-Shore</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Major</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Camposano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Muzykewicz</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>. <article-title>The natural history of epilepsy in tuberous sclerosis complex</article-title>. <source>Epilepsia</source>. <year>2010</year>;<volume>51</volume>:<fpage>1236</fpage>–<lpage>1241</lpage>.</citation>
</ref>
<ref id="bibr5-0883073812448437">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krueger</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>DN</given-names>
</name>
</person-group>. <article-title>Current management of tuberous sclerosis complex</article-title>. <source>Paediatr Drugs</source>. <year>2008</year>;<volume>10</volume>:<fpage>299</fpage>–<lpage>313</lpage>.</citation>
</ref>
<ref id="bibr6-0883073812448437">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Holmes</surname>
<given-names>GL</given-names>
</name>
<name>
<surname>Stafstrom</surname>
<given-names>CE</given-names>
</name>
</person-group>; <collab collab-type="author">Tuberous Sclerosis Study Group</collab>. <article-title>Tuberous sclerosis complex and epilepsy: recent developments and future challenges</article-title>. <source>Epilepsia</source>. <year>2007</year>;<volume>48</volume>:<fpage>617</fpage>–<lpage>630</lpage>.</citation>
</ref>
<ref id="bibr7-0883073812448437">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalantari</surname>
<given-names>BN</given-names>
</name>
<name>
<surname>Salamon</surname>
<given-names>N</given-names>
</name>
</person-group>. <article-title>Neuroimaging of tuberous sclerosis: spectrum of pathologic findings and frontiers in imaging</article-title>. <source>AJR Am J Roentgenol</source>. <year>2008</year>;<volume>190</volume>:<fpage>W304</fpage>–<lpage>W309</lpage>.</citation>
</ref>
<ref id="bibr8-0883073812448437">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shepherd</surname>
<given-names>CW</given-names>
</name>
<name>
<surname>Beard</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Kurland</surname>
<given-names>LT</given-names>
</name>
<name>
<surname>Whisnant</surname>
<given-names>JP</given-names>
</name>
</person-group>. <article-title>Tuberous sclerosis complex in Olmsted County, Minnesota, 1950-1989</article-title>. <source>Arch Neurol</source>. <year>1991</year>;<volume>48</volume>:<fpage>400</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr9-0883073812448437">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thiele</surname>
<given-names>EA</given-names>
</name>
</person-group>. <article-title>Managing epilepsy in tuberous sclerosis complex</article-title>. <source>J Child Neurol</source>. <year>2004</year>;<volume>19</volume>:<fpage>680</fpage>–<lpage>686</lpage>.</citation>
</ref>
<ref id="bibr10-0883073812448437">
<label>10</label>
<citation citation-type="web">
<collab collab-type="author">Tuberous Sclerosis Association</collab>. <article-title>Clinical guidelines for the care of patients with tuberous sclerosis complex: summary</article-title>. <comment>Available at</comment>: <ext-link ext-link-type="uri" xlink:href="http://www.tuberous-sclerosis.org/publications/clinical_guidelines_for_the_care_of_patients_with_TSC.pdf">http://www.tuberous-sclerosis.org/publications/clinical_guidelines_for_the_care_of_patients_with_TSC.pdf</ext-link>. <comment>Accessed September 19, 2011</comment>.</citation>
</ref>
<ref id="bibr11-0883073812448437">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devlin</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Morrison</surname>
<given-names>PJ</given-names>
</name>
</person-group>. <article-title>Tuberous sclerosis complex: clinical features, diagnosis, and prevalence within Northern Ireland</article-title>. <source>Dev Med Child Neurol</source>. <year>2006</year>;<volume>48</volume>:<fpage>495</fpage>–<lpage>499</lpage>.</citation>
</ref>
<ref id="bibr12-0883073812448437">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vries</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>PF</given-names>
</name>
</person-group>. <article-title>The psychopathologies of children and adolescents with tuberous sclerosis complex (TSC): a postal survey of UK families</article-title>. <source>Eur Child Adolesc Psychiatry</source>. <year>2007</year>;<volume>16</volume>:<fpage>16</fpage>–<lpage>24</lpage>.</citation>
</ref>
<ref id="bibr13-0883073812448437">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Callaghan</surname>
<given-names>F</given-names>
</name>
</person-group>. <article-title>Tuberous sclerosis complex</article-title>. <source>Pediatr Child Health</source>. <year>2007</year>;<volume>18</volume>:<fpage>30</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr14-0883073812448437">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohtsuka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ohmori</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Oka</surname>
<given-names>E</given-names>
</name>
</person-group>. <article-title>Long-term follow-up of childhood epilepsy associated with tuberous sclerosis</article-title>. <source>Epilepsia</source>. <year>1998</year>;<volume>39</volume>:<fpage>1158</fpage>–<lpage>1163</lpage>.</citation>
</ref>
<ref id="bibr15-0883073812448437">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Epilepsy surgery in tuberous sclerosis complex: emphasis on surgical candidate and neuropsychology</article-title>. <source>Epilepsia</source>. <year>2010</year>;<volume>51</volume>:<fpage>2316</fpage>–<lpage>2321</lpage>.</citation>
</ref>
<ref id="bibr16-0883073812448437">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moavero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cerminara</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges</article-title>. <source>Childs Nerv Syst</source>. <year>2010</year>;<volume>26</volume>:<fpage>1495</fpage>–<lpage>1504</lpage>.</citation>
</ref>
<ref id="bibr17-0883073812448437">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Connolly</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>Hendson</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Steinbok</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Tuberous sclerosis complex: a review of the management of epilepsy with emphasis on surgical aspects</article-title>. <source>Childs Nerv Syst</source>. <year>2006</year>;<volume>22</volume>:<fpage>896</fpage>–<lpage>908</lpage>.</citation>
</ref>
<ref id="bibr18-0883073812448437">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roth</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Olasunkanmi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>MacAllister</surname>
<given-names>WS</given-names>
</name>
<etal/>
</person-group>. <article-title>Quality of life following epilepsy surgery for children with tuberous sclerosis complex</article-title>. <source>Epilepsy Behav</source>. <year>2011</year>;<volume>20</volume>:<fpage>561</fpage>–<lpage>565</lpage>.</citation>
</ref>
<ref id="bibr19-0883073812448437">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Karenfort</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kruse</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Freitag</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Pannek</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Tuxhorn</surname>
<given-names>I</given-names>
</name>
</person-group>. <article-title>Epilepsy surgery outcome in children with focal epilepsy due to tuberous sclerosis complex</article-title>. <source>Neuropediatrics</source>. <year>2002</year>;<volume>33</volume>:<fpage>255</fpage>–<lpage>261</lpage>.</citation>
</ref>
<ref id="bibr20-0883073812448437">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>de Vries</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Humphrey</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McCartney</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Prather</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hunt</surname>
<given-names>A;</given-names>
</name>
<name>
<surname>TSC</surname>
<given-names>Behaviour Consensus Panel</given-names>
</name>
</person-group>. <article-title>Consensus clinical guidelines for the assessment of cognitive and behavioural problems in tuberous sclerosis</article-title>. <source>Eur Child Adolesc Psychiatry</source>. <year>2005</year>;<volume>14</volume>:<fpage>183</fpage>–<lpage>190</lpage>.</citation>
</ref>
<ref id="bibr21-0883073812448437">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Crino</surname>
<given-names>PB</given-names>
</name>
<name>
<surname>Nathanson</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Henske</surname>
<given-names>EP</given-names>
</name>
</person-group>. <article-title>The tuberous sclerosis complex</article-title>. <source>N Engl J Med</source>. <year>2006</year>;<volume>355</volume>:<fpage>1345</fpage>–<lpage>1356</lpage>.</citation>
</ref>
<ref id="bibr22-0883073812448437">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Roach</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>MR</given-names>
</name>
<name>
<surname>Northrup</surname>
<given-names>H</given-names>
</name>
</person-group>. <article-title>Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria</article-title>. <source>J Child Neurol</source>. <year>1998</year>;<volume>13</volume>:<fpage>624</fpage>–<lpage>628</lpage>.</citation>
</ref>
<ref id="bibr23-0883073812448437">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bombardieri</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pinci</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moavero</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Cerminara</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Early control of seizures improves long-term outcome in children with tuberous sclerosis complex</article-title>. <source>Eur J Paediatr Neurol</source>. <year>2010</year>;<volume>14</volume>:<fpage>146</fpage>–<lpage>149</lpage>.</citation>
</ref>
<ref id="bibr24-0883073812448437">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hallett</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Blieden</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Valentim</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Burden of disease and unmet needs in tuberous sclerosis complex with neurological manifestations: systematic review</article-title>. <source>Curr Med Res Opin</source>. <year>2011</year>;<volume>27</volume>:<fpage>1571</fpage>–<lpage>1583</lpage>.</citation>
</ref>
<ref id="bibr25-0883073812448437">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Anisya-Vasanth</surname>
<given-names>AV</given-names>
</name>
<name>
<surname>Satishchandra</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nagaraja</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Swamy</surname>
<given-names>HS</given-names>
</name>
<name>
<surname>Jayakumar</surname>
<given-names>PN</given-names>
</name>
</person-group>. <article-title>Spectrum of epilepsy in tuberous sclerosis</article-title>. <source>Neurol India</source>. <year>2004</year>;<volume>52</volume>:<fpage>210</fpage>–<lpage>212</lpage>.</citation>
</ref>
<ref id="bibr26-0883073812448437">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beghi</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Frigeni</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Beghi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>De Compadri</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Garattini</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>A review of the costs of managing childhood epilepsy</article-title>. <source>Pharmacoeconomics</source>. <year>2005</year>;<volume>23</volume>:<fpage>27</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr27-0883073812448437">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jacoby</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Buck</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Baker</surname>
<given-names>G</given-names>
</name>
<name>
<surname>McNamee</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Graham-Jones</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Chadwick</surname>
<given-names>D</given-names>
</name>
</person-group>. <article-title>Uptake and costs of care for epilepsy: findings from a U.K. regional study</article-title>. <source>Epilepsia</source>. <year>1998</year>;<volume>39</volume>:<fpage>776</fpage>–<lpage>786</lpage>.</citation>
</ref>
<ref id="bibr28-0883073812448437">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pillas</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Selai</surname>
<given-names>C</given-names>
</name>
</person-group>. <article-title>Economic aspects of epilepsy and antiepileptic treatment: a review of the literature</article-title>. <source>Expert Rev Pharmacoecon Outcomes Res</source>. <year>2005</year>;<volume>5</volume>:<fpage>327</fpage>–<lpage>338</lpage>.</citation>
</ref>
<ref id="bibr29-0883073812448437">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoon</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Frick</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Carr</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>Austin</surname>
<given-names>JK</given-names>
</name>
</person-group>. <article-title>Economic impact of epilepsy in the United States</article-title>. <source>Epilepsia</source>. <year>2009</year>;<volume>50</volume>:<fpage>2186</fpage>–<lpage>2191</lpage>.</citation>
</ref>
<ref id="bibr30-0883073812448437">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romanelli</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Verdecchia</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rodas</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Seri</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Epilepsy surgery for tuberous sclerosis</article-title>. <source>Pediatr Neurol</source>. <year>2004</year>;<volume>31</volume>:<fpage>239</fpage>–<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr31-0883073812448437">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Weiner</surname>
<given-names>HL</given-names>
</name>
</person-group>. <article-title>Tuberous sclerosis and multiple tubers: localizing the epileptogenic zone</article-title>. <source>Epilepsia</source>. <year>2004</year>;<volume>45</volume>(<issue>suppl 4</issue>):<fpage>41</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr32-0883073812448437">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lewis</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Murphy</surname>
<given-names>KC</given-names>
</name>
<name>
<surname>Sampson</surname>
<given-names>JR</given-names>
</name>
</person-group>. <article-title>Genotype and psychological phenotype in tuberous sclerosis</article-title>. <source>J Med Genet</source>. <year>2004</year>;<volume>41</volume>:<fpage>203</fpage>–<lpage>207</lpage>.</citation>
</ref>
<ref id="bibr33-0883073812448437">
<label>33</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raznahan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>NP</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Humphrey</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yates</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>PF</given-names>
</name>
</person-group>. <article-title>Biological markers of intellectual disability in tuberous sclerosis</article-title>. <source>Psychol Med</source>. <year>2007</year>;<volume>37</volume>:<fpage>1293</fpage>–<lpage>1304</lpage>.</citation>
</ref>
<ref id="bibr34-0883073812448437">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raznahan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Joinson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>O'Callaghan</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>PF</given-names>
</name>
</person-group>. <article-title>Psychopathology in tuberous sclerosis: an overview and findings in a population-based sample of adults with tuberous sclerosis</article-title>. <source>J Intellect Disabil Res</source>. <year>2006</year>;<volume>50</volume>(<issue>pt 8</issue>):<fpage>561</fpage>–<lpage>569</lpage>.</citation>
</ref>
<ref id="bibr35-0883073812448437">
<label>35</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Joinson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>O'Callaghan</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Osborne</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Martyn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bolton</surname>
<given-names>PF</given-names>
</name>
</person-group>. <article-title>Learning disability and epilepsy in an epidemiological sample of individuals with tuberous sclerosis complex</article-title>. <source>Psychol Med</source>. <year>2003</year>;<volume>33</volume>:<fpage>335</fpage>–<lpage>344</lpage>.</citation>
</ref>
<ref id="bibr36-0883073812448437">
<label>36</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brooks-Kayal</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Molecular mechanisms of cognitive and behavioral comorbidities of epilepsy in children</article-title>. <source>Epilepsia</source>. <year>2011</year>;<volume>52</volume>(<issue>suppl 1</issue>):<fpage>13</fpage>–<lpage>20</lpage>.</citation>
</ref>
<ref id="bibr37-0883073812448437">
<label>37</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Curatolo</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Napolioni</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Moavero</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Autism spectrum disorders in tuberous sclerosis: pathogenetic pathways and implications for treatment</article-title>. <source>J Child Neurol</source>. <year>2010</year>;<volume>25</volume>:<fpage>873</fpage>–<lpage>880</lpage>.</citation>
</ref>
<ref id="bibr38-0883073812448437">
<label>38</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zaroff</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Devinsky</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Miles</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Barr</surname>
<given-names>WB</given-names>
</name>
</person-group>. <article-title>Cognitive and behavioral correlates of tuberous sclerosis complex</article-title>. <source>J Child Neurol</source>. <year>2004</year>;<volume>19</volume>:<fpage>847</fpage>–<lpage>852</lpage>.</citation>
</ref>
<ref id="bibr39-0883073812448437">
<label>39</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kurth</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lewis</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>AM</given-names>
</name>
</person-group>. <article-title>Health care resource utilization in patients with active epilepsy</article-title>. <source>Epilepsia</source>. <year>2010</year>;<volume>51</volume>:<fpage>874</fpage>–<lpage>882</lpage>.</citation>
</ref>
<ref id="bibr40-0883073812448437">
<label>40</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ivanova</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Birnbaum</surname>
<given-names>HG</given-names>
</name>
<name>
<surname>Kidolezi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Mallett</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Caleo</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Direct and indirect costs associated with epileptic partial onset seizures among the privately insured in the United States</article-title>. <source>Epilepsia</source>. <year>2010</year>;<volume>51</volume>:<fpage>838</fpage>–<lpage>844</lpage>.</citation>
</ref>
<ref id="bibr41-0883073812448437">
<label>41</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunt</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>A comparison of the abilities, health and behaviour of 23 people with tuberous sclerosis at age 5 and as adults</article-title>. <source>J Appl Res Intellect Disabil</source>. <year>1998</year>;<volume>11</volume>:<fpage>227</fpage>–<lpage>238</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>